EUVIMEDEUVIMED entdecken
Crossref

Prevalence of Hepatitis D in the United States

Derek L Stark iD, Seyi Falekun, Shane Jorgensen, Patricia Slev

The Journal of Applied Laboratory Medicine · 03.09.2025 · 10 (5) · 1133-1139

DOI: 10.1093/jalm/jfaf092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 08.07.2025. Verfasst von Derek L Stark und 3 weiteren Autor:innen. Beteiligte Einrichtung: ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, United States. Hauptthemen laut MEDLINE: Hepatitis D, Hepatitis Delta Virus, Hepatitis B. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis D virus (HDV) causes the most severe form of viral hepatitis and exclusively infects people who are also infected with hepatitis B virus (HBV). The global incidence of HDV is estimated to be 5.9%–14.6% of HBV infected individuals, however, the prevalence in the United States is unknown.

Methods

In this study, the prevalence of HDV in HBV infected individuals was determined by testing 1104 samples from a national laboratory that were positive for hepatitis B surface antigen with the anti-HDV total antibody ELISA from International Immuno Diagnostics.

Results

The prevalence of HDV using the described approach was 1.2% of HBV positive samples. HDV positivity did not correlate with HBV viral load, although the sample size may be insufficient to detect such an effect. HDV RNA, which is present during active infection, was detected in 33% of anti-HDV positive samples.

Conclusions

This provides a more reliable estimate for HDV prevalence in the United States that is lower than estimates from previous smaller studies and meta-analyses. A reliable estimate of HDV prevalence is increasingly important due to the advent of several new HDV therapies and the growing consensus among clinicians and professional societies that all HBV infected individuals should also be screened for HDV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis DHepatitis Delta VirusHepatitis BHumansUnited StatesPrevalenceViral LoadAdultFemaleMaleRNA, ViralHepatitis B virusEnzyme-Linked Immunosorbent AssayMiddle AgedHepatitis B Surface AntigensHepatitis AntibodiesAdolescentYoung AdultAgedChild

Substanzen

RNA, ViralHepatitis B Surface AntigensHepatitis Antibodies

Autor:innen und Institutionen

  • ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, United States.
  • Rocky Mountain Laboratories, Draper, UT, United States.
  • ARUP Laboratories, Salt Lake City, UT, United States.
  • Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, United States.

ORCID-Profile: Derek L Stark

Zitieren

APA

Stark, D. L., Falekun, S., Jorgensen, S., & Slev, P. (2025). Prevalence of Hepatitis D in the United States. The Journal of Applied Laboratory Medicine, 10(5), 1133-1139. https://doi.org/10.1093/jalm/jfaf092

Vancouver

Stark DL, Falekun S, Jorgensen S, Slev P. Prevalence of Hepatitis D in the United States. The Journal of Applied Laboratory Medicine. 2025;10(5):1133-1139. doi:10.1093/jalm/jfaf092

BibTeX
@article{Stark2025,
  author = {Stark, Derek L and Falekun, Seyi and Jorgensen, Shane and Slev, Patricia},
  title = {Prevalence of Hepatitis D in the United States},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2025},
  volume = {10},
  number = {5},
  pages = {1133--1139},
  doi = {10.1093/jalm/jfaf092}
}
Kostenlos starten →